Related Experiment Videos
[Tumor markers in prostate cancer]
1Dept. of Urology, Gifu University School of Medicine, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|September 1, 1994
Summary
Prostate-specific antigen (PSA) aids in prostate cancer follow-up, but differentiating early cancer from benign conditions remains challenging. Advanced assays like PSA-protease inhibitor complex and PSA-density show promise for earlier prostate cancer detection.
Area of Science:
- Oncology
- Biochemistry
Context:
- Prostate cancer diagnosis and management rely on accurate tumor markers.
- Prostate-specific antigen (PSA) is a key marker, but its specificity is limited by benign prostatic hyperplasia (BPH).
Purpose:
- To review the current role of tumor markers, particularly PSA, in prostate cancer diagnosis and follow-up.
- To explore advancements in PSA assay systems for improved early detection and differentiation from BPH.
Summary:
- Serum PSA levels can be elevated in both prostate cancer and BPH, complicating early diagnosis.
- Newer methods, including PSA-protease inhibitor complex and PSA-density, offer improved accuracy in detecting early-stage prostate cancer.
- Serial PSA monitoring is crucial for evaluating treatment efficacy and detecting disease progression in prostate cancer patients.
Impact:
- Enhanced diagnostic capabilities for early-stage prostate cancer.
- Improved patient management through accurate monitoring of treatment response and disease recurrence.
- Potential for earlier intervention and better patient outcomes in prostate cancer care.